Z
Zhongwu Lai
Researcher at AstraZeneca
Publications - 54
Citations - 4093
Zhongwu Lai is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Cancer. The author has an hindex of 17, co-authored 43 publications receiving 2907 citations.
Papers
More filters
Journal ArticleDOI
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress,Cloud P. Paweletz,Enriqueta Felip,Byoung Chul Cho,Daniel Stetson,Brian Dougherty,Zhongwu Lai,Aleksandra Markovets,Ana Vivancos,Yanan Kuang,Dalia Ercan,Sarah E Matthews,Mireille Cantarini,J. Carl Barrett,Pasi A. Jänne,Geoffrey R. Oxnard +15 more
TL;DR: Analysis of cell-free plasma DNA collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD 9291 provides insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291.
Journal ArticleDOI
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Zhongwu Lai,Aleksandra Markovets,Miika Ahdesmaki,Brad Chapman,Oliver Hofmann,Robert McEwen,Justin Johnson,Brian Dougherty,J. Carl Barrett,Jonathan R. Dry +9 more
TL;DR: VarDict will greatly facilitate application of NGS in clinical cancer research and performs amplicon aware variant calling for polymerase chain reaction (PCR)-based targeted sequencing often used in diagnostic settings, and is able to detect PCR artifacts.
Journal ArticleDOI
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Harveer Dev,Harveer Dev,Ting-Wei Will Chiang,Chloé Lescale,Inge de Krijger,Alistair Martin,Domenic Pilger,Julia Coates,Matylda Sczaniecka-Clift,Wenming Wei,Matthias Ostermaier,Mareike Herzog,Jonathan Lam,Abigail Shea,Mukerrem Demir,Qian Wu,Fengtang Yang,Beiyuan Fu,Zhongwu Lai,Gabriel Balmus,Gabriel Balmus,Rimma Belotserkovskaya,Violeta Serra,Mark J. O'Connor,Alejandra Bruna,Petra Beli,Luca Pellegrini,Carlos Caldas,Ludovic Deriano,Jacqueline J.L. Jacobs,Yaron Galanty,Stephen P. Jackson +31 more
TL;DR: Reduced SHLD1/2 expression in human breast cancers displaying intrinsic or acquired PARP-inhibitor resistance is documented, highlighting this potential for patient stratification and yield new treatment opportunities.
Journal ArticleDOI
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine Anne Eberlein,Daniel Stetson,Aleksandra Markovets,Katherine Al-Kadhimi,Zhongwu Lai,Paul R. Fisher,Catherine B. Meador,Paula J. Spitzler,Eiki Ichihara,Sarah Ross,Miika Ahdesmaki,Ambar Ahmed,Laura E. Ratcliffe,Elizabeth L. Christey O'Brien,Claire Barnes,Henry Brown,Paul D. Smith,Jonathan R. Dry,Garry Beran,Kenneth S. Thress,Brian Dougherty,William Pao,Darren Cross +22 more
TL;DR: The detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells with acquired resistance to current and newly developed EGFR tyrosine kinase inhibitors, including AZD9291, and NRAS modifications in tumor samples from patients who have progressed on current or EGFR inhibitors in development are described.
Journal ArticleDOI
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cristina Cruz,Marta Castroviejo-Bermejo,Sara Gutiérrez-Enríquez,Alba Llop-Guevara,Yasir H. Ibrahim,Albert Gris-Oliver,Sandra Bonache,Beatriz Morancho,Alejandra Bruna,Oscar M. Rueda,Zhongwu Lai,Urszula M. Polanska,Gemma N Jones,Petra Kristel,L. de Bustos,Mario Guzmán,Olga Rodriguez,Judit Grueso,Gemma Montalban,Ginevra Caratu,Francesco M. Mancuso,Roberta Fasani,J. Jimenez,William J. Howat,Brian Dougherty,Ana Vivancos,Paolo Nuciforo,Xavier Serres-Créixams,Isabel T. Rubio,Ana Oaknin,Elaine Cadogan,J.C. Barrett,Carlos Caldas,Carlos Caldas,J. Baselga,Cristina Saura,J. Cortés,Joaquín Arribas,Jos Jonkers,Orland Diez,Mark J. O'Connor,Judith Balmaña,Violeta Serra +42 more
TL;DR: In this paper, the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi were investigated.